Skip to Main Content

Paper Details

Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing.
European Journal of Drug Metabolism and Pharmacokinetics
1
2021
AR-42, CL, HDAC, Hematologic, Human, Malignancies, Patients, REC-2282, Solid Tumors, Tumor, acute myeloid leukemia, histone deacetylase, human, malignancy, patient, patients
Author NameAffiliation
Craig C HofmeisterWinship Cancer Institute of Emory University
  • 1 - 1

Datasets

Release 1.2